AVANOS MEDICAL (AVNS) CFO surrenders shares for taxes on RSU vesting

Rhea-AI Filing Summary

AVANOS MEDICAL, INC. SVP and Chief Financial Officer Scott Michael Galovan reported a compensation-related share transaction. On April 22, 2026, 4,228 shares of common stock were surrendered to the company to satisfy tax withholding obligations when 12,225 time-based restricted share units vested. This was a tax-withholding disposition rather than an open-market sale. After the transaction, Galovan directly held 135,596 shares of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Galovan Scott Michael

Role SVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	4,228	$24.64	$104K

Holdings After Transaction: Common Stock — 135,596 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares surrendered for taxes: 4,228 shares Price per share for tax withholding: $24.64 per share Shares held after transaction: 135,596 shares +1 more

4 metrics

Shares surrendered for taxes 4,228 shares Tax-withholding disposition on April 22, 2026

Price per share for tax withholding $24.64 per share Value used for 4,228 surrendered shares

Shares held after transaction 135,596 shares CFO’s direct common stock holdings following disposition

Vesting TRSUs 12,225 units Time-based restricted share units that vested April 22, 2026

Key Terms

time-based restricted share units (TRSUs), tax withholding obligations, economic equivalent

3 terms

time-based restricted share units (TRSUs) financial

"Reflects shares surrendered to the Issuer to satisfy tax withholding obligations upon the vesting of 12,225 time-based restricted share units (TRSUs)"

tax withholding obligations financial

"Reflects shares surrendered to the Issuer to satisfy tax withholding obligations upon the vesting of 12,225 time-based restricted share units"

economic equivalent financial

"Each TRSU is the economic equivalent of one share of Common Stock"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Galovan Scott Michael

(Last) (First) (Middle)

5405 WINDWARD PARKWAY

SUITE 100

(Street)

ALPHARETTA GEORGIA 30004

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AVANOS MEDICAL, INC. [ AVNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/22/2026		F(1)		4,228	D	$24.64	135,596	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares surrendered to the Issuer to satisfy tax withholding obligations upon the vesting of 12,225 time-based restricted share units (TRSUs) which: (i) were awarded to the Reporting Person on April 22, 2025 and (ii) vested on April 22, 2026. Each TRSU is the economic equivalent of one share of Common Stock.

Remarks:

	/s/ John Hurley, as attorney-in-fact for Scott M. Galovan	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did AVANOS MEDICAL (AVNS) CFO report in this Form 4 filing?

The CFO reported surrendering 4,228 common shares to the company to cover tax withholding when 12,225 time-based restricted share units vested. This was a tax-withholding disposition, not an open-market sale, and reflects routine handling of equity compensation.

Was the AVNS CFO’s Form 4 transaction an open-market sale of shares?

No. The 4,228 AVNS shares were surrendered to the issuer to satisfy tax withholding obligations tied to vesting restricted share units. This type of Form 4 transaction does not involve selling shares into the market and is a standard compensation-related event.

How many AVANOS MEDICAL shares does the CFO hold after this Form 4 event?

Following the tax-withholding disposition, the CFO directly holds 135,596 shares of AVANOS MEDICAL common stock. This figure reflects his remaining ownership after 4,228 shares were surrendered back to the company for tax purposes on the vesting date.

What equity award vested for the AVNS CFO in this Form 4 filing?

A grant of 12,225 time-based restricted share units vested for the AVNS CFO. Each time-based restricted share unit is economically equivalent to one share of common stock, and part of the resulting shares was surrendered to cover associated tax withholding obligations.

What does transaction code F mean in the AVNS CFO’s Form 4?

Transaction code F indicates a tax-related disposition, where shares are delivered to the issuer to pay an exercise price or satisfy tax withholding. In this case, 4,228 AVNS shares were surrendered to cover taxes on vesting restricted share units, not sold on the open market.